You just read:

Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases

News provided by

Mallinckrodt plc

Jul 18, 2019, 06:46 ET